| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Podlesak Dennis serves as a Director at SNDX. Across recent SEC filings that breaks down to 1 buy and 6 sells. Those positions are worth an estimated $1.5M at current prices.
Historically, Podlesak Dennis's trades have earned a middling insider score of 62/100 across 6 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +23.3%.
The biggest single holding is SNDX (~$1.5M) as Director. The recent filings there lean toward selling, a net 122,448 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | SNDX Syndax Pharmaceuticals Inc | Director | Sale+OE | 57,600 | $15.19 | $875,099.52 | -23.1% | +8.3% | - | |
| Sep 16, 2022 | SNDX Syndax Pharmaceuticals Inc | Director | Sale+OE | 78,815 | $24.08 | $1,897,987.53 | -51.0% | +4.6% | -25.0% | |
| Apr 22, 2021 | SNDX Syndax Pharmaceuticals Inc | Director | Buy | 13,967 | $14.11 | $197,077.16 | +47.6% | +7.5% | +15.7% |